Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients
| Errataetall: |
CommentOn: N Engl J Med. 2020 May 7;382(19):1787-1799. - PMID 32187464 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Travel medicine and infectious disease - 38(2020) vom: 30. Nov., Seite 101749 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eljaaly, Khalid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.12.2020 Date Revised 10.01.2021 published: Print-Electronic CommentOn: N Engl J Med. 2020 May 7;382(19):1787-1799. - PMID 32187464 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tmaid.2020.101749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310544459 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310544459 | ||
| 003 | DE-627 | ||
| 005 | 20231225140329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tmaid.2020.101749 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310544459 | ||
| 035 | |a (NLM)32473994 | ||
| 035 | |a (PII)S1477-8939(20)30228-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eljaaly, Khalid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: N Engl J Med. 2020 May 7;382(19):1787-1799. - PMID 32187464 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Tablets |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Al-Tawfiq, Jaffar A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 38(2020) vom: 30. Nov., Seite 101749 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g day:30 |g month:11 |g pages:101749 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2020.101749 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |b 30 |c 11 |h 101749 | ||